Hideyuki Mishima

Nagakute, 4801195, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 80 publications

A case of nodular fasciitis that appeared in the breast and required differentiation from a malignant tumor.

A case of nodular fasciitis that appeared in the breast and required differentiation from a malignant tumor.

Journal: Journal of medical ultrasonics (2001)

Published: January 09, 2025

Comprehensive genomic evaluation of advanced and recurrent breast cancer patients for tailored precision treatments.

Comprehensive genomic evaluation of advanced and recurrent breast cancer patients for tailored precision treatments.

Journal: BMC cancer

Published: April 06, 2023

NY-ESO-1-specific redirected T cells with endogenous TCR knockdown mediate tumor response and cytokine release syndrome.

NY-ESO-1-specific redirected T cells with endogenous TCR knockdown mediate tumor response and cytokine release syndrome.

Journal: Journal for immunotherapy of cancer

Published: June 02, 2022

Phase 3 trial of sequential versus combination treatment in colorectal cancer: The C-cubed study.

Phase 3 trial of sequential versus combination treatment in colorectal cancer: The C-cubed study.

Journal: European journal of cancer (Oxford, England : 1990)

Published: January 30, 2022

Effects of Goshajinkigan (TJ-107) for oxaliplatin-induced peripheral neurotoxicity using the functional assessment of cancer therapy/gynecologic oncology group 12-item neurotoxicity questionnaire in a Phase II, multicenter, randomized, double-blind, placebo-controlled trial.

Effects of Goshajinkigan (TJ-107) for oxaliplatin-induced peripheral neurotoxicity using the functional assessment of cancer therapy/gynecologic oncology group 12-item neurotoxicity questionnaire in a Phase II, multicenter, randomized, double-blind, placebo-controlled trial.

Journal: Journal of cancer research and therapeutics

Published: December 17, 2021

Multicenter, single-arm, phase II study of the continuous use of panitumumab in combination with FOLFIRI after FOLFOX for RAS wild-type metastatic colorectal cancer: Exploratory sequential examination of acquired mutations in circulating cell-free DNA.

Multicenter, single-arm, phase II study of the continuous use of panitumumab in combination with FOLFIRI after FOLFOX for RAS wild-type metastatic colorectal cancer: Exploratory sequential examination of acquired mutations in circulating cell-free DNA.

Journal: International journal of cancer

Published: December 11, 2021

A Study on the Status of End-of-Life Chemotherapy for Solid Cancer after the Introduction of New Anti-Cancer Drugs

A Study on the Status of End-of-Life Chemotherapy for Solid Cancer after the Introduction of New Anti-Cancer Drugs

Journal: Gan to kagaku ryoho. Cancer & chemotherapy

Published: January 20, 2021

Phase II study of an oxaliplatin-based regimen for relapsed colon cancer patients treated with oxaliplatin-based adjuvant chemotherapy (INSPIRE study).

Phase II study of an oxaliplatin-based regimen for relapsed colon cancer patients treated with oxaliplatin-based adjuvant chemotherapy (INSPIRE study).

Journal: Cancer chemotherapy and pharmacology

Published: November 03, 2020

Efficacy of celecoxib as preemptive analgesia for patients undergoing laparoscopic inguinal hernia repair: a randomized trial.

Efficacy of celecoxib as preemptive analgesia for patients undergoing laparoscopic inguinal hernia repair: a randomized trial.

Journal: Surgery today

Published: July 30, 2020

Impact of sex and histology on the therapeutic effects of fluoropyrimidines and oxaliplatin plus bevacizumab for patients with metastatic colorectal cancer in the SOFT trial.

Impact of sex and histology on the therapeutic effects of fluoropyrimidines and oxaliplatin plus bevacizumab for patients with metastatic colorectal cancer in the SOFT trial.

Journal: Global health & medicine

Published: May 22, 2020

Phase Ib/II Study of Biweekly TAS-102 in Combination with Bevacizumab for Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies (BiTS Study).

Phase Ib/II Study of Biweekly TAS-102 in Combination with Bevacizumab for Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies (BiTS Study).

Journal: The oncologist

Published: April 29, 2020

Phase II study of 5-fluorouracil-leucovorin plus bevacizumab for chemotherapy-naïve older or frail patients with metastatic colorectal cancer (OGSG 0802).

Phase II study of 5-fluorouracil-leucovorin plus bevacizumab for chemotherapy-naïve older or frail patients with metastatic colorectal cancer (OGSG 0802).

Journal: International journal of clinical oncology

Published: December 14, 2019

Showing 1-12 of 80

Last Updated: 09/26/2026